ReviewTuberculosis (Edinburgh, Scotland)2009
The Mycobacterium tuberculosis MEP (2C-methyl-d-erythritol 4-phosphate) pathway as a new drug target.
Review in Tuberculosis (Edinburgh, Scotland), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 67 citations in OpenAlex.
- Targeting IspD for Anti-infective and Herbicide Development: Exploring Its Role, Mechanism, and Structural Insights.Journal of medicinal chemistry · 2025Review
- Actinomycetes - The Repertoire of Diverse Bioactive Chemical Molecules: From Structures to Antibiotics.Current topics in medicinal chemistry · 2025Review
- Arginine to glutamine mutation in the substrate binding region impaired the isopentenyl activity ofMolecular biology research communications · 2024Article
- Investigating Novel IspE Inhibitors of the MEP Pathway in Mycobacterium.Microorganisms · 2023Article
- Genetic Underpinnings of Carotenogenesis and Light-Induced Transcriptome Remodeling in the Opportunistic PathogenPathogens (Basel, Switzerland) · 2023Article
- Differential Regulation of an OsIspH1, the Functional 4-Hydroxy-3-Methylbut-2-Enyl Diphosphate Reductase, for Photosynthetic Pigment Biosynthesis in Rice Leaves and Seeds.Frontiers in plant science · 2022Article
- Structural and biophysical characterization of the Burkholderia pseudomallei IspF inhibitor L-tryptophan hydroxamate.Bioorganic & medicinal chemistry letters · 2021Article
- Immuno-antibiotics: targeting microbial metabolic pathways sensed by unconventional T cells.Immunotherapy advances · 2021Review
- The novel potential biomarkers for multidrug-resistance tuberculosis using UPLC-Q-TOF-MS.Experimental biology and medicine (Maywood, N.J.) · 2020Article
- MEPicides: α,β-Unsaturated Fosmidomycin Analogues as DXR Inhibitors against Malaria.Journal of medicinal chemistry · 2018Article
- Cell-wall synthesis and ribosome maturation are co-regulated by an RNA switch in Mycobacterium tuberculosis.Nucleic acids research · 2018Article
- The Methylerythritol Phosphate Pathway: Promising Drug Targets in the Fight against Tuberculosis.ACS infectious diseases · 2018Review
- A structural and functional study on the 2-C-methyl-d-erythritol-4-phosphate cytidyltransferase (IspD) from Bacillus subtilis.Scientific reports · 2016Article
- Semi-automated curation of metabolic models via flux balance analysis: a case study with Mycoplasma gallisepticum.PLoS computational biology · 2013Article
- A whole-cell phenotypic screening platform for identifying methylerythritol phosphate pathway-selective inhibitors as novel antibacterial agents.Antimicrobial agents and chemotherapy · 2012Article
- Functional characterization and evolution of the isotuberculosinol operon in Mycobacterium tuberculosis and related Mycobacteria.Frontiers in microbiology · 2012Article
- Innovative therapy for Classic Galactosemia - tale of two HTS.Molecular genetics and metabolism · 2012Review
- Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs.Bioorganic & medicinal chemistry letters · 2011Article
- 1-Deoxy-D-xylulose 5-phosphate synthase catalyzes a novel random sequential mechanism.The Journal of biological chemistry · 2011Article
- Identification of novel small molecule inhibitors of 4-diphosphocytidyl-2-C-methyl-D-erythritol (CDP-ME) kinase of Gram-negative bacteria.Bioorganic & medicinal chemistry · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Tuberculosis (TB) is still a major public health problem, compounded by the human immunodeficiency virus (HIV)-TB co-infection and recent emergence of multidrug-resistant (MDR) and extensively drug resistant (XDR)-TB. Novel anti-TB drugs are urgently required. In this context, the 2C-methyl-d-erythritol 4-phosphate (MEP) pathway of Mycobacterium tuberculosis has drawn attention; it is one of several pathways vital for M. tuberculosis viability and the human host lacks homologous enzymes. Thus, the MEP pathway promises bacterium-specific drug targets and the potential for identification of lead compounds unencumbered by target-based toxicity. Indeed, fosmidomycin is now known to inhibit the second step in the MEP pathway. This review describes the cardinal features of the main enzymes of the MEP pathway in M. tuberculosis and how these can be manipulated in high throughput screening campaigns in the search for new anti-infectives against TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.